Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus Bevacizumab in untreated advanced renal cell carcinoma
NCT03693573Phase 3Withdrawn
- Sponsor
- Roche
- Start
- Jan 2019
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of atezolizumab in renal cell carcinoma (RCC), sponsored by Roche. Planned start Jan 2019; status: withdrawn.
02
Drugs
atezolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03693573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693573.